NanoPhoria Bioscience, a Milan, Italy-based pre-clinical stage biotech company, received a €17.5M award from EIC accelerator program, including a grant of €2.5M and a conditional equity investment of up to €15M.
The company intends to use the funds to support advancement of its lead product for heart failure through first-in-human studies.
Led by CEO Claudio De Luca, NanoPhoria provides a platform that allows selective targeting at the organ and/or cellular level. The core vehicle of the platform is an inorganic calcium-phosphate nanoparticle that is a versatile, non-viral, biomimetic nano-carrier that can be loaded with active biologics. The lead product coming out of the platform is a treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome affecting the lives of millions worldwide.
It will extend its research into clinical trials, to translate initial remarkable preclinical observations into better treatment options and a potential paradigm change in the treatment of heart failure.
FinSMEs
26/02/2025